Friday, January 6, 2017

BRIEF-Adamas announces FDA acceptance of ADS-5102 new drug application

* Adamas announces FDA acceptance of ADS-5102 new drug

application for the treatment of levodopa-induced dyskinesia in

patients with parkinson's disease

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)